Evidence map›Paper›PMID 20013087›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2009

Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis.

Shinji Sugahara, Hidetsugu Nakayama, Kuniaki Fukuda, Masashi Mizumoto, Mari Tokita, Masato Abei, Junichi Shoda, Yasushi Matsuzaki, Eriko Thono, Koji Tsuboi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 8 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 8 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Guideline
  8. Guideline
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Shinji SugaharaDepartment of Radiation Oncology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan. ssuga@pmrc.tsukuba.ac.jp
Hidetsugu Nakayama
Kuniaki Fukuda
Masashi Mizumoto
Mari Tokita
Masato Abei
Junichi Shoda
Yasushi Matsuzaki
Eriko Thono
Koji Tsuboi
Koichi Tokuuye
University of Tsukuba · JPBrown University · USKasumigaura Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe prognosis of patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor, as effective treatment options are limited. The authors performed a retrospective review to evaluate the efficacy of proton-beam therapy (PBT) for patients presenting with PVTT in the setting of HCC. PATIENTS AND

methodsBetween February 1991 and September 2005, 35 patients with HCC and tumor thrombi in the main trunk or major branches of the portal vein presented for consideration of PBT. Their tumor sizes ranged from 25 mm to 130 mm (median, 60 mm). A median total dose of 72.6 GyE in 22 fractions was delivered over 31 days to a target volume that encompassed both the primary hepatic lesion and the PVTT.

results32 patients were progression-free during a median follow-up period of 21 months (range, 2-88 months) and three patients experienced disease progression. Local progression-free survival rates were 46% at 2 years and 20% at 5 years, and the median local progression-free survival was 21 months. Acute toxicity > or = grade 3 was observed in three patients, and no patient experienced late toxicity > or = grade 3. None of the patients had to discontinue treatment as a result of toxicity.

conclusionPBT improved local control and significantly prolonged survival in HCC patients with PVTT.

Indexed as

Proton TherapyAdultAgedAged, 80 and overCarcinoma, HepatocellularCombined Modality TherapyDisease-Free SurvivalDisease ProgressionDose Fractionation, RadiationFemaleFollow-Up StudiesHumansLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedProtons

Identifiers

PMID20013087
OpenAlexW1577058893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.